Document is current
Any future updates will be listed below
-
Authors
Ling, Sikai
Zhang, Xue
Dai, Yao
Jiang, Zhuofan https://orcid.org/0009-0009-1999-8687
Zhou, Xujiao
Lu, Sicong https://orcid.org/0000-0002-9054-7303
Qian, Xiaoqing
Liu, Jianping https://orcid.org/0000-0002-7336-3895
Selfjord, Niklas https://orcid.org/0009-0008-5628-5849
Satir, Tugce Munise https://orcid.org/0000-0001-9021-1650
Lundin, Anders
Touza, Julia Liz
Firth, Mike
Van Zuydam, Natalie
Bilican, Bilada
Akcakaya, Pinar https://orcid.org/0000-0001-8413-8995
Hong, Jiaxu https://orcid.org/0000-0001-9912-633X
Cai, Yujia https://orcid.org/0000-0002-2955-7289
- License Information
-
More Information
Article History
Received: 28 September 2023
Accepted: 17 December 2024
First Online: 10 February 2025
Competing interests
: S. Ling and Y.C. have a patent (ZL201910979334.0) on RIDE applied via Shanghai Jiao Tong University. Y.C. is a co-founder and advisor of BDGENE Therapeutics. T.M.S., A.L., B.B., N.S., J.L.T., M.F. and P.A. are employees and shareholders of AstraZeneca. The other authors declare no competing interests.
